Edwards Lifesciences Corporation, Edwards Lifesciences LLC v. Cardiovalve Ltd.

N OTE: This disposition is nonprecedential.
United States Court of Appeals
for the Federal Circuit
______________________
EDWARDS LIFESCIENCES CORPORATION,
EDWARDS LIFESCIENCES LLC,
Appellants
v.
CARDIOVALVE LTD.,
Appellee
______________________
2023-1515
______________________
Appeal from the United States Patent and Trademark
Office, Patent Trial and Appeal Board in No. IPR2021-
01051.
______________________
Decided: June 9, 2025
______________________
J OSHUA STOWELL , Knobbe, Martens, Olson & Bear,
LLP, Irvine, CA, argued for appellants. Also represented
by BRIAN C. BARNES , CRAIG S. S UMMERS .
SARA T ONNIES H ORTON, Willkie Farr & Gallagher LLP,
Chicago, IL, argued for appellee. Also represented by
D EVON WESLEY EDWARDS , New York, NY; D AVID P HILLIP
EMERY , WILLIAM MANDIR, Sughrue Mion, PLLC, Washing-
ton, DC.
Case: 23-1515 Document: 43 Page: 1 Filed: 06/09/2025

-- 1 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 2
______________________
Before M OORE, Chief Judge, HUGHES and C UNNINGHAM ,
Circuit Judges.
CUNNINGHAM , Circuit Judge.
Edwards Lifesciences Corporation and Edwards
Lifesciences LLC (collectively, “Edwards”) appeal from a fi-
nal written decision of the Patent Trial and Appeal Board
in an inter partes review of U.S. Patent No. 10,702,385. In
the final written decision, the Board granted Cardiovalve
Ltd.’s (“Cardiovalve”) non-contingent Motion to Amend and
Supplemental Motion to Amend, canceling original claims
1–10 and replacing those claims with substitute claims
11–20 and concluded that Edwards failed to show that
claims 11–20 are unpatentable. Edwards Lifesciences
Corp. v. Cardiovalve Ltd., No. IPR2021-01051, Paper 36 at
58–59 (P.T.A.B. Dec. 6, 2022) (“Decision”).1 For the reasons
below, we affirm.
I. BACKGROUND
Cardiovalve owns the ’385 patent, which is titled “Im-
plant for Heart Valve.” ’385 patent; see also Decision at 2.
The ’385 patent is generally directed to methods of using “a
prosthetic valve support” that facilitates “minimally inva-
sive (e.g., transcatheter and/or transluminal) implantation
of a prosthetic valve at a native valve of a subject.” ’385
patent col. 1 ll. 56–59; see id. col. 27 l. 14 to col. 28 l. 59.
On June 4, 2021, Edwards petitioned for inter partes
review of claims 1–10 of the ’385 patent. Decision at 2; J.A.
209. Edwards asserted six grounds of unpatentability,
1 Citations in this opinion are to the version of the
Board’s decision in the Joint Appendix. See J.A. 1–60.
Case: 23-1515 Document: 43 Page: 2 Filed: 06/09/2025

-- 2 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 3
including that Goldfarb2 anticipated or rendered obvious
claims 1–2 and 4–10 of the ’385 patent and that the combi-
nation of Goldfarb and Goldfarb ’3293 rendered claim 3 ob-
vious. Decision at 9–10; J.A. 229. Edwards’s
unpatentability arguments rely on an embodiment of Gold-
farb, which the parties and the Board refer to as “Embodi-
ment A.” Decision at 10, 16–22; J.A. 229.
Embodiment A is an embodiment of Goldfarb in which
a “fixation device” (depicted in Fig. 22A–22B below as ele-
ment 14) has “distal and proximal elements” (elements 18
and 16 respectively) on each side of the fixation device that
can move towards each other to capture tissue flaps and
“lateral branches” (elements 19A, 19B) and/or the distal el-
ements (element 18) that can move independently of each
other.4 J.A. 1380 at col 27. ll. 6–10, 57–60.
2 U.S. Patent No. 7,563,267 (filed May 19, 2003; is-
sued July 21, 2009), J.A. 1294–396 (“Goldfarb”).
3 U.S. Patent No. 7,635,329 (filed Sep. 27, 2005; is-
sued Dec. 22, 2009) (“Goldfarb ’329”). ’329 patent; see De-
cision at 10 n.6.
4 Goldfarb “does not contain a picture of Embodi-
ment A.” J.A. 236. The parties agree that the “description
of Figures 22A–22B largely still applies to Embodiment A,
as evidenced by the use of the same reference numerals to
identify the common features across the embodiments.”
J.A. 236 (citing J.A. 1380 col. 27 l. 6 to col. 28 l. 9); Appel-
lee’s Br. 14; see also Decision at 18–19.
Case: 23-1515 Document: 43 Page: 3 Filed: 06/09/2025

-- 3 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 4
J.A. 1312 (rotated); see also Decision at 19. As shown in
Figures 22A–22B, fixation device 14 includes coupling
member 19, which “is bifurcated into two resilient and flex-
ible branches 19A, 19B” which can move from the position
shown in Fig. 22A to the one shown in Fig. 22B. J.A. 1380
col. 27 ll. 10–14. Fixation device 14 also includes a “collar
131” that is positioned around coupling member 19. Id.
col. 27 ll. 24–27 (“A collar 131 is slidably disposed over cou-
pling member 19”); see also id. col. 27 ll. 46–48.
Goldfarb describes male and female elements of cou-
pling member 19. Specifically, “fixation device 14 is cou-
pled to the shaft 12 by a coupling mechanism.” J.A. 1373
col. 14 ll. 58–61. One embodiment of the coupling mecha-
nism includes “an upper shaft 20 and a detachable lower
shaft 22 which are interlocked at a joining line or mating
surface 24.” J.A. 1373 col. 14 ll. 61–63. As depicted below,
mating surface 24, J.A. 1302, Fig. 5A, can be a “sigmoid
curve defining a male element and female element” on the
upper shaft of coupling member 19 which “interlock respec-
tively with corresponding female and male elements” on
the lower shaft. J.A. 1374 col. 15 ll. 19–23.
Case: 23-1515 Document: 43 Page: 4 Filed: 06/09/2025

-- 4 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 5
Appellant’s Br. 14, 16 (rotating and annotating J.A. 1312);
see also id. at 15 (annotating J.A. 1302).
On December 10, 2021, the Board instituted inter
partes review. Decision at 2. On March 7, 2022, Cardio-
valve filed a Motion to Amend pursuant to 37 C.F.R.
§ 42.121. Id.; J.A. 390; J.A. 101. On September 28, 2022,
Cardiovalve filed a Revised Supplemental Motion to
Amend to “correct[ ] certain deficiencies in the original Mo-
tion to Amend” and to “clarify[ ] that the Motion to Amend
is non-contingent.” Decision at 2–3 & n.1. The
Case: 23-1515 Document: 43 Page: 5 Filed: 06/09/2025

-- 5 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 6
Supplemental Motion to Amend (1) canceled original
claims 1–10; (2) substituted independent claim 11 for orig-
inal claim 1; and (3) changed the dependency of claims 1–
10 from canceled claim 1 to substitute claim 11, resulting
in substitute dependent claims 12–20. Decision at 3 n.1, 9.
Substitute claim 11 recites:
11. A method for use at a native valve of a heart of
a subject, the valve including a first leaflet and a
second leaflet, the method comprising:
transluminally advancing, to the heart, an
implant coupled to a delivery apparatus,
the implant including a first clip, a
second clip, and a support portion
flexibly coupled to the first and sec-
ond clips, the support portion hav-
ing an opening that surrounds a
central longitudinal axis of the im-
plant, the first clip and the second
clip fixedly coupled to each other,
the first clip including a first-clip
arm, and the second clip including
a second-clip arm, the first-clip arm
and the second-clip arm each hav-
ing an end most displaceable from
the central longitudinal axis of the
implant, and
the delivery apparatus including a
delivery tube and at least one clip
controller disposed within the de-
livery tube,
the first-clip arm, the second-clip
arm, and the support portion being
disposed within the delivery tube
during the transluminal advancing
to the heart;
Case: 23-1515 Document: 43 Page: 6 Filed: 06/09/2025

-- 6 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 7
advancing the implant out of the delivery
tube by advancing the end of the first-clip
arm and the end of the second-clip arm out
of the delivery tube before advancing the
support portion out of the delivery tube;
forming the first leaflet and the second
leaflet into a double-orifice arrangement by
using the implant to couple a middle scal-
lop of the first leaflet to a middle scallop of
the second leaflet by, using the clip control-
ler:
opening the first clip by deflecting
the first-clip arm;
independently of opening the first
clip, opening the second clip by de-
flecting the second-clip arm;
gripping the first leaflet with the
first clip by closing the first clip by
deflecting the first-clip arm; and
independently of gripping the first
leaflet, gripping the second leaflet
with the second clip by closing the
second clip by deflecting the sec-
ond-clip arm;
decoupling the clip controller from the im-
plant; and
withdrawing the delivery apparatus from
the subject.
J.A. 395–96 (emphasis added for limitations added by
amendment and deletions incorporated); Decision at 7–9.
Two limitations from substitute claim 11 are at issue
in this appeal: (1) “a support portion flexibly coupled to the
first and second clips, the support portion having an
Case: 23-1515 Document: 43 Page: 7 Filed: 06/09/2025

-- 7 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 8
opening that surrounds a central longitudinal axis of the
implant” (the “support portion” limitation); and (2) “ad-
vancing the implant out of the delivery tube by advancing
the end of the first-clip arm and the end of the second-clip
arm out of the delivery tube before advancing the support
portion out of the delivery tube” (the “advancing” limita-
tion).
On December 6, 2022, the Board granted the Motion to
Amend filed by Cardiovalve because Edwards failed to
show by a preponderance of the evidence that the proposed
substitute claims were unpatentable. Decision at 1–2. The
Board focused its analysis on the unpatentability of substi-
tute claim 11 based on Goldfarb. See id. at 10, 16–18 (ac-
knowledging that Edwards had agreed “that substitute
claims 12–20 thus stand or fall with substitute claim 11”);
J.A. 433.
Edwards timely appealed. We have jurisdiction under
28 U.S.C. § 1295(a)(4)(A).
II. STANDARD OF REVIEW
“We review the Board’s legal conclusions de novo and
its fact findings for substantial evidence.” Game & Tech.
Co. v. Wargaming Grp. Ltd., 942 F.3d 1343, 1348
(Fed. Cir. 2019). “Substantial evidence means such rele-
vant evidence as a reasonable mind might accept as ade-
quate to support a conclusion.” Fanduel, Inc. v. Interactive
Games LLC, 966 F.3d 1334, 1343 (Fed. Cir. 2020) (internal
quotation marks and citation omitted).
“Anticipation is a question of fact as is the question of
what a reference teaches.” In re NTP, Inc., 654 F.3d 1279,
1297 (Fed. Cir. 2011). “We review the Board’s legal deter-
mination of obviousness de novo and its factual findings for
substantial evidence.” Outdry Techs. Corp. v. Geox S.p.A.,
859 F.3d 1364, 1367 (Fed. Cir. 2017). “We review claim
construction de novo and any subsidiary factual findings
based on extrinsic evidence for substantial evidence.”
Case: 23-1515 Document: 43 Page: 8 Filed: 06/09/2025

-- 8 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 9
Apple Inc. v. MPH Techs. Oy, 28 F.4th 254, 259
(Fed. Cir. 2022).
III. D ISCUSSION
In its briefing on appeal, Edwards argued that the
Board erred by (1) adopting an implicit construction of
“support portion” that excluded the male element portion
of the coupling member, Appellant’s Br. 34, 39–51; (2) find-
ing that Goldfarb’s male element does not have an opening
that “surrounds” the central longitudinal axis of the fixa-
tion device, id. at 35, 51–57; (3) finding that Goldfarb does
not disclose or render obvious the “advancing” limitation,
i.e., that the ends of the clip arms are advanced out of the
delivery tube before the support portion, id. at 36, 57–60;
(4) finding that Goldfarb’s collar does not satisfy the “sup-
port portion” limitation, id. at 36, 60–66; and (5) miscon-
struing “advancing” and “having an end most
displaceable,” id. at 36, 66–72. However, at oral argument,
Edwards asserted only “three independent bases for re-
mand,” namely that the Board (1) misconstrued support
portion to require a unitary structure; (2) erred in finding
that “collar” is not a support portion; and (3) erred in its
construction of the “advancing” limitation and in conclud-
ing that the limitation was not disclosed by teachings of the
references asserted. Oral Arg. 1:00–2:41, https://oralargu-
ments.cafc.uscourts.gov/default.aspx?fl=23-1515_1008202
4.mp3; see also id. at 7:43–8:38. We address each of these
three arguments in turn.
A.
Edwards argues that the Board erred by adopting an
implicit construction of “support portion” that excludes the
male element of the coupling member of Goldfarb. Appel-
lant’s Br. 39. Cardiovalve responds that this is not a claim
construction issue—instead, Cardiovalve argues the
Board’s refusal to deem the male element of the coupling
member as a support portion was a factual finding that
rested on its interpretation of Goldfarb, not the
Case: 23-1515 Document: 43 Page: 9 Filed: 06/09/2025

-- 9 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 10
interpretation of the claims of the ’385 patent. Appellee’s
Br. 49. We agree with Cardiovalve.
The Board made a factual finding that the male ele-
ment of the coupling member alone does not constitute a
support portion. The Board held that Goldfarb’s coupling
member is “plainly a single, unitary structure.” Decision
at 41. The Board considered Edwards’s argument that the
male element portion of the coupling member is “the sup-
port portion because it: (1) bears the weight of the fixation
device during delivery; (2) absorbs and transfers the axial
and rotational forces imposed by the shaft 12; and (3) holds
the device in the correct orientation.” Id. The Board found
that all the “elements” that Edwards described as being
separate—the male and female elements of the coupling
member, the coupling member, and flexible arms 19A and
19B—“together form a solid, single component.” Id. (em-
phasis added). Accordingly, the Board concluded that the
entirety of the coupling member, i.e., “all of the[se] ‘ele-
ments’” perform the required functions of a “support por-
tion.” Id. at 41–42 (emphasis in original). The Board
further noted that Edwards “points to no disclosure of
Goldfarb . . . that suggests these elements act inde-
pendently or separately to perform the functions of the uni-
tary component, nor can we discern any such disclosure.”
Id. at 42. Thus, the Board concluded that Edwards’s argu-
ment was “an arbitrary and unduly restrictive interpreta-
tion of [Goldfarb’s] disclosure.” Id.
In sum, the Board’s analysis was not directed towards
“discern[ing] the meaning of a particular term” in substi-
tute claim 11. Trading Techs. Int’l, Inc. v. Open E Cry,
LLC, 728 F.3d 1309, 1319 (Fed. Cir. 2013). Therefore, the
Board engaged in fact finding rather than implicit claim
construction. We further agree that the portions of Gold-
farb relied on by the Board provide substantial evidence to
support its conclusion. We also conclude that the Board did
not err in finding that the male element of the coupling
member is not a support portion.
Case: 23-1515 Document: 43 Page: 10 Filed: 06/09/2025

-- 10 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 11
B.
Next, we address Edwards’s argument that the Board
erred in finding that Goldfarb’s collar is not a support por-
tion. Appellant’s Br. 60. Substitute claim 11 requires “ad-
vancing . . . an implant . . . including . . . a support portion
flexibly coupled to the first and second clips.” J.A. 395 (em-
phasis added). Thus, the plain language of substitute
claim 11 requires a support portion that is coupled to the
first and second clips when the implant is advanced. We
agree with Cardiovalve that substantial evidence supports
the Board’s finding that Goldfarb’s collar does not consti-
tute the claimed support portion. Appellee’s Br. 60–63.
The Board explained why Goldfarb’s collar does not
satisfy the claim limitation for support portion. The Board
stated that Goldfarb teaches that the collar “is slidably dis-
posed over” the coupling member. Decision at 44–45 (quot-
ing J.A. 1380 col. 27 ll. 24–27). The Board reasoned that
because the collar and coupling member can freely move
with respect to each other, Goldfarb’s collar “cannot pro-
vide the support functions” required of a support portion.
Decision at 45. Additionally, the Board explained that be-
cause moving the slidable collar with respect to the cou-
pling member “would not exert any mechanical effect on
the first and second clips,” then it follows that the “col-
lar . . . and the clips are not ‘coupled’ to each other.” Id.
We agree with the Board’s reasoning and conclude that
substantial evidence supports its determination that the
collar does not constitute the claimed support portion in
substitute claim 11. Edwards argues that “the Board ig-
nored that the collar and clips are slidably disposed only
temporarily” and that “[o]nce the collar engages the de-
tents on the coupling member, the components are perma-
nently coupled.” Appellant’s Br. 33; see also id. at 61–62
(arguing that once the groove 133 on collar 131 engage with
detents 135, “collar 131 is permanently coupled to the
clips . . . through the branches 19A, 19B and remains
Case: 23-1515 Document: 43 Page: 11 Filed: 06/09/2025

-- 11 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 12
behind with the clips after deployment of the fixation de-
vice, as shown in Figure 22B.”). Even if we accept that the
collar may eventually be permanently coupled to the clips,
Edwards’s argument fails because the collar is not coupled
to the clips at the time of delivery of the implant, as re-
quired by the claim language. As the Board recognized,
Edwards agreed that Embodiment A of Goldfarb is “deliv-
ered through the delivery tube ‘with distal and proximal
elements 16, 18 in the closed position.’” Decision at 28
(quoting J.A. 448). Goldfarb provides that, in this closed
position, the collar is “pushed distally against, but not over,
detents 135 so that branches 19A, 19B are disposed to-
gether and fixation device 14 has a minimal profile.” J.A.
1380 col. 27 ll. 31–35 (emphasis added). In other words,
the collar is not coupled to the detents, and therefore not
coupled to the clips, during delivery of the implant.
In sum, substantial evidence supports the Board’s de-
termination that Goldfarb discloses that the collar is not
coupled to the clips at the time of delivery of the implant as
substitute claim 11 requires. Therefore, we conclude that
the Board did not err in determining that Goldfarb’s collar
does not constitute a support portion.
C.
Edwards argues that the Board erred in (1) construing
the “advancing” limitation, Appellant’s Br. 66–69; and
(2) finding that Goldfarb does not disclose and render obvi-
ous the “advancing” limitation. Id. at 57–60. We address
each argument in turn.
i.
Edwards argues that the Board improperly construed
“‘advancing the end of the first-clip arm and the end of the
second-clip arm out of the delivery tube before advancing
the support portion out of the delivery tube’ to ‘require the
ends of the clips to precede any part of the support portion,
not the entire support portion, when advanced.’”
Case: 23-1515 Document: 43 Page: 12 Filed: 06/09/2025

-- 12 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 13
Appellant’s Br. 67 (emphasis in original) (quoting J.A. 480).
Specifically, Edwards argues that the proper construction
requires reading the “support portion” to refer to the entire
support portion, rather than “any part” of the support por-
tion. Id. Cardiovalve counters that, under the plain and
ordinary meaning of “advancing,” the object being ad-
vanced must only “begin[ ] to emerge from the delivery
tube” and need not “come fully out towards the native heart
valve.” Appellee’s Br. 29. We agree with Cardiovalve.
“Claim terms are generally given their plain and ordi-
nary meaning, which is the meaning one of ordinary skill
in the art would ascribe to a term when read in the context
of the claim, specification, and prosecution history.” Kyoc-
era Senco Indus. Tools Inc. v. Int’l Trade Comm’n, 22 F.4th
1369, 1378 (Fed. Cir. 2022) (citing Phillips v. AWH Corp.,
415 F.3d 1303, 1313–14 (Fed. Cir. 2005) (en banc)). As al-
ways, “[w]e start with the claim language.” Straight Path
IP Grp., Inc. v. Sipnet EU S.R.O., 806 F.3d 1356, 1360
(Fed. Cir. 2015).
The claim language indicates that the support portion
must only be partially advanced out of the delivery tube.
As the Board explained, “the language of the proposed sub-
stitute claim uses the term ‘the end of’ to indicate that the
whole clip arm is advanced out of the delivery tube, in the
phrase ‘by advancing the end of the first-clip arm and the
end of the second clip-arm.’” Decision at 54 (quoting J.A.
467). By contrast, the phrase “before advancing the sup-
port portion out of the delivery tube” does not include the
phrase “the end of.” Id. (quoting J.A. 467). We agree with
the Board that this claim language indicates that the en-
tire support portion need not be advanced out of the deliv-
ery tube.
Case: 23-1515 Document: 43 Page: 13 Filed: 06/09/2025

-- 13 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 14
The specification also supports this interpretation.
Figure 3B in the specification provides an example of the
prosthetic valve support 22 being “advanced out of delivery
tube 130.” ’385 patent col. 14 ll. 15–17. Specifically, Figure
3B shows that the clip arms emerge in their entirety, while
the prosthetic valve support 22, which includes the support
portion 60, is only partially out of the delivery tube.
’385 patent Fig. 3B; see id. col. 14 ll. 15–23. This disclosure
indicates that “advancing” an object “out of the delivery
tube” requires only partial emergence of that object. See
’385 patent col. 14 ll. 15–23. Accordingly, the Board cor-
rectly determined that “advancing the support portion out
of the delivery tube” refers to “advancing any part of the
support portion, rather than the entire support portion.”
Decision at 54 (quoting J.A. 467).
In sum, we conclude that the Board did not err in its
construction of the “advancing” limitation.
Case: 23-1515 Document: 43 Page: 14 Filed: 06/09/2025

-- 14 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 15
ii.
Edwards also argues that the Board erred in finding
that Goldfarb does not disclose or render obvious the “ad-
vancing” limitation. Appellant’s Br. 57. Cardiovalve re-
sponds that, under the Board’s construction of “advancing,”
the coupling member and the collar cannot meet the “ad-
vancing” limitation. Appellee’s Br. 36–37. We agree with
Cardiovalve that the coupling member does not meet the
limitation of “advancing the end of the first-clip arm and
the end of the second-clip arm out of the delivery tube be-
fore advancing the support portion out of the delivery tube”
as construed by the Board. 5
The Board found that Edwards failed to meet its bur-
den of showing that Goldfarb anticipates or renders obvi-
ous the “advancing” limitation. Decision at 57. The Board
based its conclusion on Figure 22A of Goldfarb, which indi-
cates that, regardless of the length of distal element 18,
“some portion of coupling member 19, and at least flexible
arms 19A and 19B, would necessarily have emerged from
the delivery tube prior to the distal ends of either distal
element 18 or proximal element 16.” Id. at 56 (emphasis in
original). The Board reasoned that “flexible arms 19A and
19B (which are part of coupling member 19) are attached
to the bases of both proximal and distal elements 16 and 18
and must therefore be advanced from the delivery tube as
the clips begin to emerge.” Id.; see J.A. 1380 col. 27 ll. 17–
19 (“Each of proximal elements 16 and distal elements 18
5 Because we find that the Board did not err in find-
ing that the collar does not constitute a support portion, we
need not address Edwards’s argument that the Board
failed to address the support functions provided by the col-
lar. For the same reason, we do not separately address the
parties’ arguments regarding whether the collar meets the
“advancing” limitation.
Case: 23-1515 Document: 43 Page: 15 Filed: 06/09/2025

-- 15 of 16 --

EDWARDS LIFESCIENCES CORPORATION v. CARDIOVALVE LTD. 16
are coupled at their proximal ends to one branch 19A or
19B of the coupling member 19.”).
Substantial evidence supports the Board’s findings.
Edwards argues that a skilled artisan “would have found it
obvious to adjust the length of the proximal and/or distal
elements so that they exited the delivery tube before the
male element.” Appellant’s Br. 58; see J.A. 50–51. The
Board explained that “the problem with [Edwards’s] argu-
ment is that it is largely speculative and based upon [Ed-
wards’s] interpretation of the Figures of Goldfarb.”
Decision at 56. Edwards did not provide an illustration of
Embodiment A within the delivery tube or identify any dis-
closure of Goldfarb that taught the “advancing” limitation
or draw the figures of Goldfarb to “any defined scale.” Id.
The Board therefore found that Edwards’s arguments that
Figures 22A and 22B of Goldfarb taught the “advancing”
limitation were “unavailing” and “largely speculative” in
that they “depend[ed] upon what the length of distal ele-
ment 18 could be.” Id. at 56–57 (emphasis in original). We
see no error in the Board’s determination that Goldfarb
does not disclose or render obvious the “advancing” limita-
tion.
IV. CONCLUSION
We have considered Edwards’s remaining arguments
and find them unpersuasive. For the above reasons, we
affirm.
AFFIRMED
Case: 23-1515 Document: 43 Page: 16 Filed: 06/09/2025

-- 16 of 16 --